Actively Recruiting
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study
Led by Nanfang Hospital, Southern Medical University · Updated on 2026-04-14
76
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the safety and effectiveness of combining platelet-rich plasma (PRP) and Botulinum Toxin Type A (BTX-A) injections to treat Androgenetic Alopecia (AGA), a common form of hair loss. This Phase 2 clinical trial involves adult patients aged 18 to 60 with specific stages of AGA. The study is randomized, controlled, and conducted at multiple centers, enrolling a total of 76 patients. Participants are divided into two groups. One group receives PRP injections combined with BTX-A during the first session, followed by PRP-only injections in the subsequent two monthly sessions. The other group receives only PRP injections every month for three months. Injections are given intradermally on defined scalp areas, with specific dosage and spacing guidelines. Both groups undergo safety evaluations 14 days after the first treatment, along with scalp care advice. Throughout the study, participants will have assessments at 1, 2, 3, and 6 months after treatment to monitor safety and measure hair density changes. These evaluations help researchers understand treatment effects over time. The total participation duration includes the treatment period and follow-up assessments, ensuring thorough monitoring of outcomes and participant well-being.
CONDITIONS
Brief Title
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Androgenetic Alopecia (AGA) at Norwood-Hamilton stage III to V or Ludwig stage I to III
- Aged between 18 and 60 years and in good general health
- No use of any medications for AGA treatment in the past 6 months
- No alopecia areata, local infection, or neuromuscular diseases
- Signed informed consent form and voluntary participation
You will not qualify if you...
- Disease duration longer than 5 years
- Does not meet diagnostic criteria for AGA
- Have coagulation disorders
- Have active skin diseases or severe systemic illnesses
- Have blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV/AIDS, or Syphilis
- Used any hair loss medications within the past 6 months
- Deemed unsuitable by investigator due to unreliability or inability to comply with study assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive injections of either PRP combined with Botulinum Toxin Type A or PRP-only into the alopecic scalp area in monthly sessions for three consecutive months.
3 monthly visits (in-person)
Duration - Up to 6 months after initial treatment
Participants undergo safety and efficacy evaluations after treatment, including a safety check 14 days after the initial injection, and assessments at 1, 2, 3, and 6 months post initial treatment.
1 visit at 14 days, then visits at 1, 2, 3, and 6 months (in-person)
Trial Site Locations
Total: 1 location
1
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
Y
Yong Miao, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here